0000822370 false 0000822370 2022-11-14 2022-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549






Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 14, 2022


Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-35527   87-0419387
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)


21250 Hawthorne Boulevard, Suite 800, Torrance, CA   90503
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (310) 214-0065



(Former name or former address, if changed, since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))


Securities registered pursuant to Section 12(b) of the Act: 


Title of each class   Trading Symbol   Name of each exchange on which registered


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 2.02 Results of Operation and Financial Condition.


On November 14, 2022, Emmaus Life Sciences, Inc. issued a press release announcing its results of operations and financial condition as of and for the three months and nine months ended September 30, 2022. A copy of the press release is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.


The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly provided in such a filing.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits


See the accompanying Index to Exhibits, which information is incorporated herein by reference.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 14, 2022 Emmaus Life Sciences, Inc.
    Name:  Yasushi Nagasaki
    Title: Chief Financial Officer







Exhibit Number  
99.1   November 14, 2022 Press Release
104   Cover Page Interactive Date File (embedded within Inline XBRL document)






EX-99.1 2 ea168520ex99-1_emmauslife.htm NOVEMBER 14, 2022 PRESS RELEASE

Exhibit 99.1



Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update


Torrance CA, November 14, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.


Recent Highlights


“We enjoyed a third straight substantial increase in quarterly net revenue due to increased sales in the Middle East North Africa region. The increase was less than anticipated because of a delay in production of product packaging specific to the region. The product is being processed and we are optimistic that the sales will be realized in Q4,” stated Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.


Dr. Niihara added, “We also are pleased to see significant decrease in the loss from operations compared to the previous quarters. We continue to discuss with stakeholder the possible restructuring or refinancing of our outstanding indebtedness and other current liabilities and will report on any transactions in this regard as they may occur.”


Financial and Operating Results


Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order purchases in 2022 compared to the same periods in 2021 due to overstocking by U.S. distributors in 2021. Net revenues in Q3 2022 increased by $0.7 million, or nearly 15%, from Q2 2022 net revenues of $4.3 million. Net revenues were positively affected by Q3 sales of Endari in the United Arab Emirates, where Endari was approved for marketing in May 2022, and, to a lesser extent, sales on an early access basis in the other Gulf Cooperation Council (GCC) countries. The company had no similar sales in Q1 2022 or in 2021.


Operating Expenses. Total operating expenses for the three months ended September 30, 2022 were $5.1 million, compared with $5.4 million for the same period in 2021. Of the decreased expenses in Q3, $0.2 million was attributable to a decrease in professional fees. Total operating expenses for the nine months ended September 30, 2022 were $15.7 million, compared with $17.4 million for the same period in 2021. The decrease was due to a $1.8 million decrease in research and development expenses related to $0.5 million in cash and $0.5 million in shares of the Company common stock paid and issued in 2021 to Kainos Medicine, Inc. (“Kainos”) to lead the clinical development of Kainos’s patented IRAK4 inhibitor. Total operating expenses in Q3 2022 decreased slightly from Q2 2022 due to $0.3 million decrease in selling expenses.


Loss From Operations. Loss from operations for the three months ended September 30, 2022 was $0.7 million, compared to $31,000 in the same period in 2021. Operating loss for nine months ended September 30, 2022 increased to $5.2 million, compared to $1.2 million for the same period last year. The increased operating loss resulted from lower net revenues in 2022 compared to 2021. Loss from operations in Q3 2022 decreased by $0.8 million, or 54.2%, from $1.4 million in Q2 2022 as a result of the increase in net revenues in Q3.





Other Income (Expense). Other income increased by $3.1 million to $0.2 million for the three months ended September 30, 2022, compared to other expense of $2.9 million in the same period in 2021. Other income in Q3 included a $5.2 million decrease in change in fair value of conversion feature derivatives and a $1.2 million increase in foreign exchange loss as compared to Q3 2021.


Net Loss. For the quarter, the company realized a net loss of $0.4 million, or $0.01 per share based on approximately 49.6 million weighted average basic and diluted common shares. This compares to net loss of $3.2 million, or $0.06 per share based on approximately 49.3 million weighted average basic and diluted common shares for the third quarter of 2021. The decrease in net loss was primarily attributable to the increase of $3.1 million in other income, partially offset by a decrease of $0.7 million in loss from operations discussed above. For the nine months ended September 30, 2022, the company incurred a net loss of $10.8 million, or $0.22 per share, based on approximately 49.4 million weighted average basic and diluted common shares. This compares to a net loss of $9.1 million, or $0.18 per share, based on approximately 49.2 million weighted average basic and diluted common shares for the nine months ended September 30, 2021. Net loss for Q3 2022 decreased by $8.5 million, or 96%, from $8.9 million in Q2 2022 because of the increase of $7.5 million in other income and a decrease of $0.8 million in loss from operations, as discussed above.


Liquidity and Capital Resources. At September 30, 2022, the company had cash and cash equivalents of $1.2 million, compared with $2.3 million at December 31, 2021. Cash and cash equivalents at September 30 included the net proceeds of $5.5 from related party loans. Based on the company’s cash and cash equivalents, anticipated future revenues, current liabilities and expected operating expenses, the company’s working capital is insufficient to meet its current liabilities and anticipated future working capital requirement for the next 12 months without restructuring or refinancing its existing indebtedness and other current liabilities and obtaining additional loans from related parties or debt or equity financing from third parties or curtailing certain operations or activities.


About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets and sells Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, in the U.S. and in the United Arab Emirates, or U.A.E., and is pursuing marketing authorization for Endari® in other Gulf Cooperation Council countries. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as certain cancers. For more information, please visit www.emmausmedical.com.


About Endari® (prescription grade L-glutamine oral powder)

Endari®, Emmaus’ prescription grade L-glutamine oral powder, is approved for marketing by the U.S. Food and Drug Administration and the U.A.E. Ministry of Health for treating sickle cell disease. Endari® is also available on a named-patient or early-access basis in France, the Netherlands, the United Kingdom, Saudi Arabia, Bahrain, Qatar, Oman, and Kuwait.






Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.


Important Safety Information

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.


Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.


The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.


For more information, please see full Prescribing Information of Endari® at: www.ENDARIrx.co/PI.


Forward-looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding possible increased sales of Endari® in the GCC countries, possible marketing approval in the Kingdom of Saudi Arabia and perhaps other countries in the Middle East North Africa (MENA) region, possible restructuring or refinancing of outstanding indebtedness or possible equity or debt financings. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including risks and uncertainties relating to the company’s working capital and ability to raise needed financing, risks inherent in the regulatory approval process and commercialization of Endari® in the MENA region, and other factors disclosed in the company’s Annual Report on Form 10-K for 2021 and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.


Company Contact:

Emmaus Life Sciences, Inc.

Willis Lee

Chief Operating Officer

(310) 214-0065, Ext. 1130



(Financial Tables Follow)





Emmaus Life Sciences, Inc.

Condensed Consolidated Statement of Operations and Comprehensive Income (Loss)

(In thousands, except share and per share amounts) (Unaudited) 


   Three Months Ended
September 30
   Nine Months Ended
September 30
   2022   2021   2022   2021 
Revenues, Net  $4,939   $5,766   $12,460   $17,590 
Cost of Goods Sold   540    445    1,943    1,311 
Gross Profit   4,399    5,321    10,517    16,279 
Operating Expenses   5,059    5,352    15,685    17,442 
Loss from Operations   (660)   (31)   (5,168)   (1,163)
Total Other Income (Expense)   234    (2,888)   (5,613)   (7,863)
Net Loss   (391)   (3,151)   (10,825)   (9,084)
Comprehensive Loss   (2,957)   (5,819)   (16,475)   (10,991)
Net Loss Per Share  $(0.01)  $(0.06)  $(0.22)  $(0.18)
Weighted Average Common Shares Outstanding   49,558,501    49,311,864    49,397,690    49,233,371 





Emmaus Life Sciences, Inc.

Condensed Consolidated Balance Sheets

(In thousands) (Unaudited)


   As of 
   September 30,
   December 31,
Current Assets:        
  Cash and cash equivalents  $1,179   $2,279 
  Accounts receivable, net   1,491    1,040 
  Inventories, net   2,739    4,392 
  Prepaid expenses and other current assets   973    1,380 
      Total Current Assets   6,382    9,091 
Property and equipment, net   79    147 
Equity method investment   16,594    17,616 
Right of use assets   2,944    3,485 
Investment in convertible bond   15,943    26,100 
Other assets   259    295 
      Total Assets  $42,201   $56,734 
Liabilities and Stockholders’ Deficit          
Current Liabilities:          
  Accounts payable and accrued expenses  $11,134   $9,189 
  Conversion feature derivative, notes payable   4,272    7,507 
  Notes payable, current portion   8,415    3,199 
  Convertible notes payable, net of discount   14,346    10,158 
  Other current liabilities   3,356    7,047 
      Total Current Liabilities   41,523    37,100 
  Notes payable, less current portion   -    1,500 
  Convertible notes payable, net of discount   -    3,150 
  Notes payable to related parties, net   3,381    - 
  Other long-term liabilities   34,886    36,434 
      Total Liabilities   79,790    78,184 
Stockholders’ Deficit   (37,589)   (21,450)
      Total Liabilities & Stockholders’ Deficit  $42,201   $56,734 






GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@!"0 MHR>@KQ[QG\0[N[O);#1YV@M(R5:9#AI#WP>PKO?'FI-I?A"\EC8K)(!$A'8M MQ_+->(:'I;ZUK5IIZ$CSG 9O1>Y_*LJDGLCQ,SQ,U*-"GNR*.ZU#>;B*:Z+* M4]@Q[CWKTVPTFRTVP2RM;>-(%7; MMVCYOKZUX]\2/#<6B:O%=V:".VN\D*O1''7'\ZGE<-3GGAJV"BJT97[H]NHK MB='\?Z-#XLR"*SOXVE/2-OE8_0&M5), M]N&)I3M:2N_,VZ*BN+B.UM9;F4D1Q(7G@3_H(3_^ [51T'I% M%Q_.O)-(T6\\.>([2]BO=.NA$_SK#=+N*G@\&L9)\R9X>,I M26+A62NM#W"O/?BTH?1;!%7=,UUA !R?E/\ ]:O048,BL.A&:R[S1DO];M+V MXVO%:*QBC/\ ST/\1^@'%:25U8]3$TW5I.FNIY]H7PH%Q9+/J]U)#*XR(8@, MK]2>]_=!7E'Q=U&&6YL-/1@TL(:23' M\.< #]*SG!*)Y6-P5"CA^:*LUU.BT379->^'%[/.G3M7NG@>UD@^&NKS."%G29D]P$QG^=>*?" MC4?!%@^I'QC#!(&"?9_-A+XZYQCIVK2.R/4PDI2H0E+>QZ>/&WA7PYX$U7Q# MX TN!&BN(H9UEB9 Q/3OSUK$NOCGXNGT2+5M.\-Q+8182ZNI$9HS)Z YX'2G M>.=:\$:A\+=8M?!R0QA+B"2X2*(H.6P#S]*N:4B_\,LW7RC_ %$IZ=_,JCI( M;OXY^(]3T87WA[PR6BM8PVH7$BLZ1MZ#&./K6O%\:+J\^%MUXDM;&W&I65Q' M!/ Y)C^8_>'?%9_P@13\$_$>5'*W.>.O[JO,_#__ "1GQ;_U^6G\S0!WMS\< M_%UQH<6K:=X;B%E#A+JZ=&:/S/0<\#I5BY^.?B/4]&%[X>\,ETM8PVH3R*SQ MQMZ#';ZU/H:+_P ,MW_RCFWF/3OOJ/X.J#\&/$^0.1<9_P"_5 '4^&?BC?\ MB?X>ZAK.GZ.+C6;%A')9(QPY/0KWQC/'M7+ZM\4_B/X82&_U[PQ90V$CA2H/ MS#VR&.#]17FWA3Q+JGAGX;Z_-I,C0S7-Y;P-.O6-2KDD>A.,4W6[+0&^'MIJ MTGB>YU#Q%=."]H\A81#)W9!YX&.?>@#U_P ;_&:ZT71?#^JZ)96\T&JPM*1< M9RA! QP?4FNA^('CW4/"7@73M=M+6WFGN6C#)+G:-R[CC!KP3Q;!*?A3X(N= MI,0^TQEO0[P<5U/Q/\?:#XB^&6AZ9IUT9;U?*>:(*?W6U-IW?C0!UFM?&V[T MSP?H%U#IT,VM:M"9?+R1%&-Q4=\G..F:Z'P;XC^(6H:G-;^(_#]O:0>1YL4Z M9PS9 V\$CH2?PKSK^Q?!WB'X;^%+36M;32-72S9K>9_NLGF-PWX_C6'X1\>^ M*/"VN7^CZ?>MX@LX05CP2Z8! #J3R!V_&@#Z@O;VVTZSEN[N9(8(EW.[G K MQ_6?BCK7B#4QI/A&U9!(=JREX]55>PK-N[LCSY5I5:OLH.RZL-+^%-Q?[ M;KQ9K%U>3-R8$E.T>Q/^%=GI_@KPWIBJ+71[52O\3)N/YFMZL+Q5XIL/"FDO M>7;@R$$0P@_-(WH/;WJK)'2J=.FKM&X, 8 Z 4CNL:,['"J,FN?\$SWE[X M9M]1OW+7-Z3<,.R GA1[ 8JQXMU)](\)ZG?1OLEB@8QMZ-T'ZT[Z7-.=4YD?Z#M5/ MP!\1M5E\4P6NMZBTUKHDDK(A\,Z1\-M M6T!FBTJULK34I0BPSSX-QL;Y2!N]3TK-O">I>(KJQ- MB+*%H"I2^9G6X@(8$[2.""!T- R1(_"7A71[S1]-MX##)(([FR@E!8>9A,L" MVVG:EH\=OIZ6I99+V#S^A4\%N@#LX;3P7;^#I M=+BEL%T!F,+J)QY>2N:?I.E^$-%L[O0=-^Q00SHTD]JLV2RE<$G)SC; M7,W7PXU"#5Y-0TY=-:);X7,5C.I\EE,/EG( X.>144?PSOAX@OKRX^RW,%PT MLJ S.FPO'L*;1_#VSGI0!TNC>"_!)T2\M=*T^RFTZ]($ZQMYBN5Z\?&6 #85B>G(Z5N^#]&U_PW:V>FW!MIK0R2M(5 M))A3 \M W&XYSR1TK-N?AWOR7EP]K+:OJDMZ8G!.5:'RP,>H/- &PV@>" MCH5KX8>*P-A/F2VM6E!W9).Y.<]2>145K\*O!5II\]E'H<#13D&0N26.#D5]LV#S M?)SLW=\9[4 \+(X MT?3(;=I!AY,;F8>A)K?HH ^1]7CFAUJ^CN 1,L[AP>NL>+?AEI7BBZ:]$CV=ZPPTL8!#_ .\/ZURUO\#$$H-S MK;F/TCB /ZFL>62>AXWU:O3JT9]4>&6B;POI9A(,?V6/&/]T5PGQIU MQ;70+?2(W'G7<@=U'4(O/ZG'Y5Q?A;XJW_AO0QIDEFEVD61 [.04'H?45!H. MGZK\3/&GVR_+- C!KAP,*B#HBU3E=61T3Q*J4U3AN]#AN5;NK _0BO8?!'Q; MCAMXM-\1LP* +'> 9R/]L?UKK_$WPST/Q&WG!#9787'FP ''3(Z&O.=0^"N MO0,WV*ZM+I.VXE#2Y91>ADJ->A*\-4>WV.IV.I1"6RNX;A#R#&X-6Z^;Q\./ M&UA)NM[&56_O03@?U%78?#_Q/3"Q_P!I(/>X'^-5SOL=2Q4_M09]!U%/=6]L MNZ>>.)?5W"_SKQ6#P;\3+[Y;C59($/4R77]!6UI_P=:=A+X@URYO#U,4;$#\ MSS3YF^AHJU26T/O.RD\;:,]X++3YSJ-ZW AM1OQ]3T ]S70H6* NNUB.1G.* MSM&T#2] M?L^F6<=NG;[04444RPHHHH **** "BBB@ MHHHH *XOQUX*T;7+234+F%X[R)>)H6"LP]#P0:**3V,ZD5*+31Y=X6\%:7J^ ML_9KJ2Y\I3T1P,_I7N^DZ/8:'8I9Z=;)! O\*CJ?4GN:**F"T.;"0BHW2U+U C%%%6=H4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D! end EX-101.SCH 4 emma-20221114.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 emma-20221114_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 emma-20221114_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nov. 14, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2022
Entity File Number 001-35527
Entity Registrant Name Emmaus Life Sciences, Inc.
Entity Central Index Key 0000822370
Entity Tax Identification Number 87-0419387
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 21250 Hawthorne Boulevard
Entity Address, Address Line Two Suite 800
Entity Address, City or Town Torrance
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90503
City Area Code 310
Local Phone Number 214-0065
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 ea168520-8k_emmauslife_htm.xml IDEA: XBRL DOCUMENT 0000822370 2022-11-14 2022-11-14 iso4217:USD shares iso4217:USD shares 0000822370 false 8-K 2022-11-14 Emmaus Life Sciences, Inc. DE 001-35527 87-0419387 21250 Hawthorne Boulevard Suite 800 Torrance CA 90503 310 214-0065 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://emmausmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea168520-8k_emmauslife.htm ea168520ex99-1_emmauslife.htm emma-20221114.xsd emma-20221114_lab.xml emma-20221114_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea168520-8k_emmauslife.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea168520-8k_emmauslife.htm" ] }, "labelLink": { "local": [ "emma-20221114_lab.xml" ] }, "presentationLink": { "local": [ "emma-20221114_pre.xml" ] }, "schema": { "local": [ "emma-20221114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "EMMA", "nsuri": "http://emmausmedical.com/20221114", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea168520-8k_emmauslife.htm", "contextRef": "From2022-11-14to2022-11-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://emmausmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea168520-8k_emmauslife.htm", "contextRef": "From2022-11-14to2022-11-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://emmausmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001213900-22-072481-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-072481-xbrl.zip M4$L#!!0 ( ^3;E4]$R\IQA$ /EI : 96$Q-C@U,C M.&M?96UM M875S;&EF92YH=&WM7>M3V[H2_\X,_X-NSIP[="YYV$D@"31W0AXT!0(G@1;Z MA5%L)1$XEK'L//CK[TJV$R=Q>-4\VMO3,X18TNYJ5[OZ:269_?].A@8:$9M3 M9GY.**E, A%38SHU^Y\3KM-+%A+_+6]N[ \JBBYAWI45_8(%JOZS)'?!EG[Y4BN@ M9S.#\$A.LF1!1(VYIF-/H[7D%RXT *Z1HBQ4JI^<5&:UR'"(73XD.M6PD=+8 M4%95%"67D%Y-L Z?2/RW[U#'(.7]M/<)I4/B8"0()?$U5F.J".Y/G4 M C-KWK?/"8=,G+3G_&G1+NV3W?]7,HD:E!AZ"76(LX=:>$A*:*)/]E"S)G^Y MSJ@'UQ>=O]7:8:5R!A]"/)1,/K5UMG8M^GN]TL_KH)_/():KS5J]I'E^]YK MV(9.P/]U$]0XK8)^;&PT39U,CLCT.@/_%50UNYMY#MUBB&X%QJ,NQF3#P/WK M'C8X>0:I':'LVK5R[8@X-];HSP#;AU^JUC,(>$2Z?/8=.3%I")C.)+*23DABVQ!;^(+]172>F] [Q%2JVW"'0TKR!/W':(FXU M;#848R6I*$DEY[#Y[PED0J^!%:&ER-&0*,^'PWYZ@44\7!?&2J(L!TLDH_1" M=P5?B+K$!B! N%=#!/<2E[,V"(#D5%P:R,@M7"\9N$MJPO6$7^Q E/B(>.\Y<.^ &U:3M2WZ7$=4?['(0P8)F1&I[]G3VG.JBI$>)C617 M2.246&T>+5IFN?&<73J2G\_- OTR?54*P"6V4\,.*<^[$%":EZTT U.N:124 M+(NU($#PT%?IHIY=DWI*!K=;T>:08.[:I.S[9PGJ!,2"HD46@MH:^IZSKV7A M*T%6>C&/>5!9X0,! ,RXJEO15CH$=I@=*GZ^#I9EC*(:8EHC)AM2\S&VC^ME MF6\4X:!\00LK"O4]-.2/7G@(8N-^&MK#I_BW;P7Q5(RI)#9HWRPA#?R!V'MH MB.T^-9,.LTHH,_O:98[#AO D 5##DH3"TT7;-4CR#/?EK!:.V O4+&>5GG@V MIKHS$/-!YN_$0NLNLT%\K_6!@;5;I,*4P9E!]3WD%P:4O')E7BXFF22G]S"% MP=-$^=]_*3N9/4\1_L]0#](+78A!30$[:XG84^>^@*;4D6"Q*@4HJUN^:#7/ MZS74.:^^@2JN&ZI?5+Y7681U53T].FIU.\[3U M-G)\QWP *UZ'0?M:JII":B:?*[X![[>R;>.T?8+VN85-&2,% "MFV;QJ]E2[3, 2S^-2\+\$N5"\F@9E.RGA:3EWTC_ M,,S;]=8Y:M?/3MOGOU''SER;N]ATD,.@H292!TC)HM,V4O);^B?$>L@9$%'D MVM2AA&]NU"?: )L0'BN:(\J58C;W&VE$8#'1K3:QF.V@K> [P3#/$NX@,H+* MR);%1/]4 F&6'#.SY)AG$LG5/9P7[:'YRO$.J9@7XX,7.ZB7^_F7 "W(ERBTV(L,NH&LEMXT$Y=_?K]=9SEOPM4F?45_P#AA_ MS(8@*//-'0="2-7+>5:9OL99.LZT0 \KD[NCFSC"G$B+BS6W0RR;C<107(QS M3Y S4:X1 X\A0JYU)?_#T5>-Y9MBG26"X1C5]"/;.;M@YP8U""@%)H9HH][^ M:$T[S>E)OYV/+0+.>8I?#V)S5IK^,/:8#>9R0$^+#S%=O##?EG,?%W=;\F8@9B-&$!A&]T $N8Z ME5AYOVO+S"C,@#0<9CX]."B?.Q)?N7]5-AQ2+G:0D? [Y%GOE^I",]5.=5*H M/K0,-B5V8);%48E:+/4I>L2E)50H_P$F,0"37/'-PV%N(1Q6=-TFG/L?Q]0D M2G0H[-X3<]@>7W:M7FRQ,()YHJPJ:CZ#ON"Q,V"V2= !PAX\J[HY[EU'CFYLCF"?*'9="C"QD5G;"UO8H']6C*OQZ:I^SL1G= MGV]7M>)WVOR6WXDCD;6&=:)\SFQ;G#YY4J,[(>>/4/@-L"I/#NH6_8]8G M)XWO3D^+NT=+_!/E:N6C0JAWB!F1)CMCL)PP?E!K_1KFN'5^R)QLWNS%M^"/ MXIXH@X]DLK\RA(Y$V@)F9\%\*:(!QD+#.Q\ 1 MK\-DGG[Z]U\%5=G=XU#-(-: P=1E2G"X+>"NX0JHLKD!BV<,0U\G:&O=M"6" M:P6JK7>KT?W]UT;WK&)A-0:W"O-+E+/*NFGITTHD+_H2'S/PGC/1Y8<64\9W M9GX=:7PPC -!+/,4P"&7S&1V\FNCP*^?A7T3)EL-9H/F_'2E+9-(\!5[ 0I& M^-R6!1- 0\, M",S'8G\'6Y;-($:+A6Z735"7&&PLM"(*A>Y0(7FTN=&C!G@\HAS&\JF_H-6!VLP?T,IE"]V@0Z8PIP&93U8J+"Q M:"?2>E0L3'DI;EU04ZP-X5DJ3\UW6*"]7V7@)P M(WTC/MWZ H,2PA(C*[3S*HZ M;QUKH_L'"!U4@N)_>B,H>3TI+K5_?0T5_'J_G&6 MMW:6?+2S-#EWB?VHRTRFF>I5>_>R>?;R=?$+7&9%NM_+<;(DF=O2GN8X62SK MOE7&Y^&%R<][9PA8>HLP8L,RSHHZ!RACB[\H [648I?EE]H6\[+8'_W(3K=\ M+N[_>2<6M0'2#,RYETQX2H[_%SH2 3VUL1@5J#,==IGQFW:RY9^PD]8D?I3R MY 4B.37SU#'CHYGD5;HJ.[>S*Q$52F M\L2H)4Z,BFRM-V>KW:3JT]K<"!&+.H\^HRHF\'G#$-W4ZTUC/T^POD;!#^^A M!ZT.9:.JUR8:57X_&/VX[X^+ER<[KXHJ'Q#L<4#Y4>VSSI5Z#_B&V#!;\K3- M#>EJ="4A/@ _(@: ,/ CDTE(YG(B:P%?/^TNWO9 )4SS[HD*RS)LZ5B-_!KV[):;#ADB-95149MPUW#D*9%3BWCG9R%TZ=";(%95 M&01/\3P5Z[;HV\23:'AW*HZC+MVWVD;>39_-C8BK/HB*E(R.,,1H<:C&ABD" MP[2 31/BN";W91WQ>*9-%FB32W7.0[\6J%,@-M;S2IF']IR!30B2=\= #E%B M J#S'R!O\ND0@%!2\FS&DSR%*D#5FFWA+HHH]XO%<1$AO@!L ]JECJ?[8C&E MB#E&@K.J:]LB?^/?O1/JB;ZY 9B4 +2$*73V$HKX@-PSK/=^XV9AD;6Z M8H/UH+C*=RXP,C5GKX.:ZQ^T)U4]]S]/RX%5D#0('V##D."C2P#3 ZC1D3@, MI&;V>M0@NOQ=V9.C!I""Q3B1(VF&% I/O3DJD+JD&R[TR7^:';H? WA!W.W> M 'UOM!!D4-REAK<&D,PPA'2/_S:(;ON=H.$^+(ZF\# 2*A!XR3^QL'8C-EBV ML-6TX;98GH-K2*^:24TFTAF,Z1Q; 2ONPK(=^]Q2KW2(D(@?[DH$0-=OLU( MN%30VVT_IQ2*'G+='W8=]*IQ^)T I+H'^$-.ER5!UP]E>^@;-MRWQ)=/[^2C MKR.)7HXDRHLO^/(4L(?$^QQ*J&)#6-6"=WX));68Z+JR@#"#5G(U] ?]_O0! M1?$RE>9AJW)^T7ZKE[>\U3G#Z& 4?O&$E_^XZ M"U.M!BA:9$D$TO'.< H^@ ,X2 8%S+N6WB4 $7HBC E"N8NF8/XN=XQJ>K@VGI$=.HB343YLKV6IPV3/,TNJIT+CI?FJA5 M.:QT*D?->&[.^ ZTDWED,S&XW_2T:OF_8]U%$S-XP/7Q?=&L$BOW*\Q=/J" M(_J8XUOZ5EX38Q?D3GKTR(Z12W5 22^T?#J5UZ+L-S^G]4I XPG(._L'9/L@ M6_W_!-GO^Q*H9JM6OT3GIZA^^:5YT#Q_/_S]L='>SQ^ *L8ZPX .@Z2E=U_N MJ2> E->\RES,O,6IH. -%S7"-9O*M,5+COY >'C>N1^97TZ*T4G$R[?'-K;B M[)E(/C_]X$^<*L7(?QTV5G8*>35#)L5B4O%?3&_ (B U<(81[\A#9W*KH^UM M=>RG<5PV\#/Y;VT!)9-[%P-40;&VG EAC07^@C5Y1UR^?5&^E69+Z%T7Z7-Q MMH&:4$W\[0LD_O@%TOTW&K[>(=W5R=ZF_8$3^<[?Y=))7OT- M_4T*\G72N-$S1_W;RC^#'^F*/KE13V^GC=ZH,CVZNN7_T,Y.]O+HZ*NNME7] M\N[VTC[^1B]PK7]?&Y*"UNQ<4>M*O;L]/2Q,;TX8/\S=X79C.JH>WHSNCG<[ MQWCWL'5_6L [)S^PZ6AGNY7!P;1V8YGY7.^>WIP>*A?C[O'AR=?QSJ#=J%?O MZ57%_#+J'>R<31O%B^FWNSOUG\:%I8]_'%I7[,=EXD7 !JM0 '0 M &5A,38X-3(P97@Y.2TQ7V5M;6%U:GL M%E0-CB7? TL=8TA"+;< ^^[93Z?&TMB>19:\NH2PO_YTSTBR9,E@)\C8#ENU M!"QKIJ=3D4[?'\,A%S/ M#)'X_J]VWYL<9+_RS"QG%Y_([4WOMQW^K=/9U_ZO6M4J?T^&.Z1[?O?;SD[. MG(LN-S$/?+5Z0)*4_!UXOA@\SB=[V5GV?6>K,.'[QX$G;.YYY(^)R7R>+ZD7X5J"\HAOAQ>W?6^_.\'/>XL :RR*F\#CS."6^8[+'=5QU<0CEW/YB0T2)V/@\\@CW#9ABEL^\25?:M60+?B]B5(2 MLUQBI!_I22#UI+("P:U42VXXZB?Y#"!C(=!X+SJO^EG1&\(N&$J> 2S+_"=P M#O[D(/>_G4>0/ .]$*Y)/-]EN&[B!7U0:MN7D"%LPT6E1.7])V"@CJ[U2&SN M@S9^Y7; B0G_^PZ)O@@#,0NH#)7]0I@FZ/[ !0.!VX>@I15R M-^+QO>0!E-9"'?-'##08:##$!)0-%+#/#;!1+G6:F-QBCS@%**@9&%+?X4+X M%YDPXYX!*X;$FW!##(2!%"(YR5FC;PN/]#E^&3X N\('82;@"R53O626YTC.3RRI3\!QAW@ 7!X,@K($M0 %F*HE"L1R0&D& MKC-.(J.$8!=$$ I_ BHK' #Z4)&]"H'Y #%]82LE!@0V @\E"XH*\KOG(\=" MZ(;;RZ4)3"+Z%@H*?!'Z$TPJNH=&B3:+#F'(P'(9 MV@M_!-8_$L> 42NA"FX;1,>AC&33E9(T\#>,:U9$Q4J7? E(>Z.0%M05)[V< M8J^7=NWE4NC2GW'Q)/;Q#QSL[%V]TB%CT#D9-<"M[S2]TH@^H:CM@*((2-8C M31G5NT:E/7-GJ]($,O)O16(]-@9#!!8XIO010(:FX#@V:70"$U< @P2X&N;[ MKN@#AJ+AP9R6 T1#,&+=@^&A:4X"UQC!?=%P>DRB1 X%U]E)([\%X:#K^8YQ MCXK4?R1_5&XKB -J5L=-4)GB/&)]&&%/71_<_ZY::4UY!RNV.0.762YIC5^H M@J@ONKK/3HX'L &"J$6WSLPF!07X(Q0O"1L,@*]J1B!#^2-T$[8);(M0\0]; MX'>Z+NN# Q%@+:" Y=+#"$<+OXK<9A,,]+B*%('O]]Q7L$4N %*05HKBQ< 4 MG"\Z:. [*"R %XWF1@4@A&29]Y(HX#%.)]"JP!Z3DQ1I=+/2< B[;( M[J=>;P\D%]C >%1U5(DHAAXQT&=P N"(+>9. XPOFF*DX\9"V@X'"88_1;?3 M;Q-N@WZC\0-?'!_PSXFO\O!JN90.\QFS730Q@%H$'P9ECK@4AWF+#NF[ F\ M*Y=F5JTUDC8ZLVR L 77G4&M$%(8#)( QN@KTF\#(H*1&",)ER:8M^5,9"X8 M+\B%V-8/\;4ZQ6&NG'V@@>AE ( )+87F@UFJ7!=HAO$Q$+%M<+S I11 MA(,PS^],V(Y'+K@)\;;-H\PWC,G4U3"DV),8#/FLG,FPA"VSW>1*@(KH%@]O M 31G"!6PIK.;[N]U(%@6AAPW%&NYE"/7!+[&BD4\F9D!Q*1P-&0[,*668;KD M#B37R;&W!R3.,>S]B+RXBL/>"N($.<\)B)>&"%#IM#M+.?^:1JO5:@3P^<@0 MRU4%Z.@.0<'B0&7NU%.7JL(,?0X-6@)7\FS5PKSS$2PNG6B:4R0IER1IJK:" M+A!YIH(,>\;?IX(+G%XM,H_5^>JKPH-V*CQHU"MZ&!B42[">>M*N(PU'Q Q) MC(P\F9C/$OJEMBTJ'HW_G_U]\E%PR_Q KMF0'\ @_P18IH.YR/Y^6/(^/#G[ M;[JVK.JJFIY36&WB9WT90\:?'5L,H%*K-( FS[&$"21DJ]43/[G^P_&&8)* 6494"-D_@J^8,"KTXA6@(X?%#5T-^H* S3'E6REUG5-\AC?^F%J# %8$ BG5 B:R4'R"T6AJ4_7'X?IQ]+>C.HH+7^GS40 X<< 4+KZ-98:?4)L]8S8RJ7GE(G,U:4\.CO)U#!! MIM9>D,QR">C4E]?Y6>W*"$#-GX'JL$(31YIA_%4NI0.P=K*V!5_K-*.Z#%SJ MY$5?B:V'C&ZVTHF8DP1YA<'3]$^I8OLY5:0(P[/JN#40?"[^"80I?+4SVF,3 M@8G]#?>TT:&1:$X(9:_0$@(_L^"5%.!HI:;-J@L7T\ '_/) M"3="7=(B7>K-&QL,S4]AP-2/2W4%'90[2=Q49#1 1:2(H\P>$>L11,\@62/' MAQ^O+N_BH!'BSZ'K!+:Y;SB6XWX@#R/A\YVCR,(2'(C2:T#E>:32Y!X:&00R M3(@R!3IW P+C&UE=S.;E-(\"\N"X]S*7,D)YRL*?%^#^E< 9 &/&'!B#V]CS M9LTA-1R71,.ZN#:7RS)## ^@:! X1PB!XG4"'_WW$YLT2 ?_AMMZRV_/.'V? M"1MO9*;::P?*I#2S8A98F(.Y<0*D >D'V4\)D7P**_T#\M97EB^_]7EPP.R>[X_! _*QK*VXKA PL1Y@&GW*"HW MT!06% '_ H-+2I@!+E?.9.%UI5BY-"'MS(P;AXR1L$P@BS1D826T"=PEI?&^ M0^6V BAIFT]N1* >_U'I5DXK-"Q,XEZ.%Z#63S).,[>'(,684O2[N"7TF"G0 G.$;3LJP9H*4JT?:0", M"J.6R&9=#+TE>US0$ CF0X[*1.L!62RW;AW@L=K0D94R4%+^*)$"ZF.B'+G[L3@'_#%1.I"T,7;)#,-9+"(65*' V!+?2<)$MFN92@DR3( MI%)E\W?J(*Z-[ Y4PE&%_A,W&)*N">/@;J:RBE!70[LC%^H:ID[D,^2[$!E) MMXK*+?UY+D2E## T(_85_)7,X' 68C-0MGWPY=+[H^/#G<']V9W!C[(O3\44 M$+N#$5E 81ADA*#Q.Q!B.F-(M&Y98 H)(H)14!>M!,6)DNP M(6+ ;E[G, ZI688!^02E$\QZ=+!I>NI&FET%UYYJ]\6B,QG*O( 35Q)W)8& MI27"'IF8/Q7WJ%98<)X,X@B#A*@&KAX# 14#85?BD$]#H6T!'Y#B&/O0L.?N ME@TXY"YGTTAC%7+%F&WL>'Y4'&(FEKUETZ5JAR.[D'X+4YKTKT/_0*O*VCOB MSYXLH$=[U)X/[B/JI3'@3A^331DPV5C? 9\R@F"=&2/P2*P//D=@9C>13@:B MR.&(RC]P4* 4TE"9@&'Y2^VOA^X'[O=\^?>6:$$WPW),:C#NP&IMG-'(T%GV M4H:]/7%9Q(%(QD"+@@%&:"LCP&O7@S 5PH]QEMGFHS?A$P^]?#]P9:KM<=L+ MA84\'CD^&5C,&VT)B^_DMI&T+UF P<(),QZG+5UQNA/C$&AY!$2J734'P1XA M]QG*]E5FY\#5"%(*&SC9YY#.@=)"_":\$3>WA*E/)D?843P(@%?7*@3ORW@W M 6ZSO&= &>92IY^OS[:$5=A1-;=;;%^7&>YJ M8![3?Y?+5@PE(003@ .94J#R&E+1O5%:C-DJ$Z ML>5#!%&3^.P#$5E31F(^]7K3KDSNA8]'),AXOM,]O\M=%CWC4<*J9U0'C4=0)1D0]7P) MRR_B9YP7C25@?<85WKPHQ@1W62*1<'T;"&)5+X18W MUG6(+W#3<"K%>;?**F[DX^:7O./2M*Q@RSKQHPPY&4 PL3E'_QJST.UITB>8>/HZB8(JXZ1I6P?'5",<92G):R!^"XL9497;3E M>&'[7]ZRNC:X;RM\B!!S^8]H#5IU_W=9&9 =@SCNE_A9H.AYP\1WO\"*K6BK M!6=)F!K>?!HU'?1@64(V>E)5+P0Z UGG5T^ZX1,-IA@,.!8[8#JYSULAMU@. M>T)G('I@]T 0;B['9H\/K:GG)%"E$#<4A\*"K]0GK-;;#C$#)43UI!O>!$$* M_V9P #"FJ)*/_B9)=LM<"Q]P=L+*S'#T^//O>LA<@SH5^)7EZ:DZR9QKD?!D_31PM4RPZ$!2X?P5U83XC:<[&K M%WQ^2GJGY^?7W9.3L\M/O^U4=^3?M]?=7O1WA+3*Q1C@H"%Y!K"- M?CN %,;T1[CVZB^+&^Z.A-;#NYMH D@\96=(Q!JU])T(@>].9@6!G]R=1+=/ ML-'('DY1'KU?1GAW)]/Q2.\*%WKYVTYSYRDH6L"Y'A_=R3[Y"]5?=8IED,/C MFZ-4"]P/4;T^*[W$/?<"%_K^[F:-5$/_<89A6^8ZR/YEEJ)MSU+>I+*TS1V0 M;/>M.^SOZM4ZU6MMJC<:>PF[C 8+/41#_R7M_BP^ ()NXF;;2^[/+B)R+K], MH^(4(V>_EC?!NSF#=F:^+0]/VSFJTTZM,Y>.O D2E+TNZ0W::C8WDW1-I_5F M=4-I;]%&Y_MI_R'S^U,UOV?6-SOE 9F#!SWL'( Q.!F;QX-ZO?'3\T"CG7KMC0NTIFDOPH6B X7L[)]< M?/SKVG4&(HX-GN3UHIS,=?RU3L;Q/S=>4<0T:$W/".VUB-&JM*&UUH::)M5; M2PKJ=7ULWDE%FXXJ#5IM9(3PTV$KF&E#_^FYH#5HL_T6;D >4*^_C#:LWM-. MS^B9[F84C>2[S6S*EQUNKW R:@MXVN*I:%"MV5X'0C0@)!,VSR5D):YUYT@= M;Y=_XDW1'-%K]74)?G9UVFZOA98 YFN+:TF!A+1H>U7J^EW(.CU2IV@8ZZP% MCM6HUE@+0B!M:>N9L.0U*.G0:GL!"%DMHJ;;%%:BH3KM-!;((U>J>+GK1J/)BN.^XN2D-FT M63D)>B9O63D)VN)AS8LBY-&?T;E;W?#]6+(M:X.: MRK:S+>Z)=NWZ6[MVV*Y=_VG:M5];+].]X$6^<.Z)8[U6\\:[.9W6Q\R2KZ:[ M'7%>Z).V\7,IR5;G5!MSP1//]/UO6(/N$O7N.:\Y3/O.'QKGR>;7Y8K[B4FZ M^*CDB].Z>#2[0=S6?YS;J>-KLIYT+1M*?B\\AE4MX\-&K>/'6HI;S2>Z*]7/N8<4SYK-:S2. M4BW;R+(9/:]Z7@_.>K6\IO6@:\BS/O#8"H.##O0M3O$DZJ*+ QJM+U)575'K M%*UF6V/7K1,A*;4S^RO8JJ..?EF!M'3:RC;_OUI=B=8Z"Y1E"S>L)3M8U,]K ME\L7JL6O*\L>&\Y2;O?)V=:Z[Z?3>FLRUFBM_3)-]T4#SG=I\[R?JBLE'8!M MOC";(,RWKL8.K68]]^I5>O%PY]K%P]VC Q(ATI7'LJ_$;R[;CUU@B%-?LE%] M]0'.J3KL;_89N':V\A[MNRU M!*8WJ59=96+WPZF":N3=E@Q ?WL4YDCOO,P3(!L8_[]JW)\IW'W?X\(ZU;-= M1YNAQ"_#@4:3MK)]_J\?[Z_(A3S_Q54ZM.^AYA6>F9IY[]VM[QCW(_EZB_C] M12<&S_DXMOB:[WL%:3D-TS.V9OPGGM78!X[V;"'N4;M-1!V(8;\&F! M^3O9MDASLJ91K?!'P!8AI$.U]CH^^3ZSY?K4B]_ERHV+9U:9U;S?14&<1. M"P_?NNP,U#N(@A44&^NT5E^RO%<@-56J-19XOF3M$]&K>2]>WOP"0HW6&AF% MV8P,] 6YT*+5[ [&ZV>A*]@]/=\F9:YKM*&_M0746GF%Z;6L"RX5"5GXVJ$5 MAT/[:^-,(8Q=A\V&30F%UD9P>#+#1K7_I:Q.O:?6D@\%39CKKZHG$.*2]MIT M<"ZI2^L3 ZC U7+@/I^[XRT+7>NTW7Z+76M-6E^'+937V07/)P2+;L"L6]%N/QOKV:/SPX2M//-F?GO;EW[$IV?(!9WWNI9M%4S)WXNA1 MX\8ZK#_OE)>;P.+[T3$A\TYSF;O4Q.$*.ZF[Y9$?GOB7P\7$J2]RM)PC7R+) MX#$FX<_D,28I(E^;BS-:]/[XZN2O(_SE\]W%^='_ U!+ P04 " /DVY5 MY81^!E0# #(# $0 &5M;6$M,C R,C$Q,30N>'-DM5;;TT#2!@90P@10Z36_PPBCV)M%4EEQ);M*_1Y+MW!/B 'Z25N>(_,U7V*,.A18 MU$!G(L1=/A2GZ!N)H8$^ P=)M)"GZ(:PU%I$AS*0J"WBA($&LY!Y:J"C2G \ M0!COH7L#/!+R^K([TQUKG:B&[T\FDPH7CV0BY+VJA"+>3["OB4[53*TZK>;? M?O1SJL(9V2>3(_5F>DGO1L#?IKT?=Q_#6_+UVZOP0D^^=$[2'_?C]#9Y.[B* MCZ^>/K&JBGZ.VVFG]K-].[KKGF4NFRH<0TR0.0RN6I[-+T]O4J\(.?)KU6K@ MWYWW^@[G9<#&E%%^OPD>G)R<^&ZU@*XAIP/)"NFZ;Y<'1,%,V:S2'7C*E28\ M7,)'>D98!!_YV>(2E&Z$'F=06D C6,$I""LC\>B;!8.OU0I@JO"(D&0&'A(U M<*)*:JS2Q($?Z@7<6#="ES0M53\EH#:KNJ4EPJ?S\P\S+,0Q254,$0T)LZ7I MH$$0O#8-QB &KCM"QF+/VR2?K[92TZ0KI$9\K3%W78_9Q=X3 MH9/:0;$S7/"P->&@ANM!9:JB>:1E@ICO0+D@"MX!06RYI#?Y5]O@=N!*:%^G MLVLY?P7V<;J1XP/3JK#\50A+;T[Y0![JBT(X,Y6.9?7MVR^.XADT,>0"A_HW M*2P^DG]Q'DZFU($LE7:DI6\EK&@55P-<"[:'\R>FFZN#&B(4*=?RJ4Q3+%** MR6&5.?^]*5<'V2'84CC4[0%5L.Y\4PDT_4S-#'\#4$L#!!0 ( ^3;E66 M4YSP_@H ("& 5 96UM82TR,#(R,3$Q-%]L86(N>&ULS9U=;^.X%8;O M"_0_L.Y-"XSCB8-=(-G)+C*>9&%L-DECSVS;1;&@)<81(I,!)2?VOR\IB;)$ M\DA*BI*]CGC]G9Y/)Z^OK$64O^)7QI^PH8IMA%2YRG&^SNK:/NX_5GS+\ M4YK0IS/YUPIG!(GC1;.S79:)Q0 M>=PB,E)1LA9;W/'IZ>FD*%520[E;\53MXV2B[-0UB]*D0]]PDB5G66'OFD4X M+[J]=S<(5,C_C95L+#>-CZ?CD^.C71:/U,$OCB!G*;DG#ZAHYEF^?Q8H98DD M851M>^3DP6XFY7PBXR>4K'%.8KFC4[FCX^_ECOY:;;[&*Y*.D%0*/L!VG;;J MJH(FKLW>$9ZP^)*^S[4>[>1.6+,?IN\PW(YW;OB'O.^*' M./='6HSSY'U'NA'Y?[&=FY;??'CMQS65&Z_%IY9%LLO%!$9B95)6T3$"%WLH M)H:J[KIV%K7J3>5HSKC9=CDS%G5F)#I:LY=)3!)1]W0J/XSEAZ+9XC]_S)A8 M"5RLLISC*%L[':7D8R_ 'SC;6 MW5:M9I;"/])5'5\>%K$+P&A+QDG&MCPB;^J5IEOH*%6.-JE0R"45H>.OB]&/ MA0;]KE3_^30YU.*@H\42:+LA-%^*&BTM:!>[ZF:;*=7+S;(@.MEB2.]C)4%2 MX[B#+\2.8[GSJQ2O+?:UNCO MM*W/!59Q$- ,<0C.%LT@5$=YXNB"TBU.[\DSXUWXM&6NJ;&9U&%I:H)BQ&(, M1*/4HE+LB8A_;,49.^'IOA<*0^F:"\"JCH8F"XH.NS<0D%KNEY$EQS1+Y #6 M"XDI=7ZZ 9@U3CTT75"< .;@4Y):[Y>4Q2-)4WD_ -/^ <4F=DT+;%CGQ50& M10QH#V2FB$!52#C87+[(U;E8)@UL;$/O$Q[#=A<_M3A8A'2' RDJPI",\T12 MXS9$#T.&TC4]@%6=&TT6%#%V;R KI1P5>O^07-)X$"*US@\@FDT['I4H0#C: MSOK0$&J?8%PE6833TLN5V)9U-,^B=0T(:%>'Q! &!0KD#H2E#%#,%"%>@?D7 MP7P8+@VE'U@,JW94:EF H.C>^C"1>B^0S+:P'CCB<;S/>+).J9*DRA M6S0@HVTV=%5 < #6 #HJ-5K,9SYGDB7>S6,!:O*0E,^#]U "ZMW"TF.[S0P@ M#@B=;H< 02((M:-\@C2G$>//K/&XPXQMQ0"XG[$87J'T1+F%:E 3VFAUA@0$ MV!"? &:MT _E,RF(R?=XB@J0K,$+<1=Q+ Y45OUSG5!R#+;?JG5+5X?=-E,6 M84 DP>X ?BKE!_4!R1AT2T.!9OJ&ID[]0S,="LTT:&BF[X%F^;D#4T] M\0_-R5!H3H*&YN1=T(B.]SK6S,3'6[YDK[:'LT&E%V1,JU9@#K+P<#&\]<$B M ^1Z1H;XQ*186-WR.\Y>$AK!2V9([@48P+25&DT;'CIV@WW\U MB%>=UK"D7 MY;U?$B7S,\JT3=J'F%(3'B1M8[V#2ZGVB<0=RW*<_CMY[CP1MXN]X&$U;(6D MI0P/%9N]/F#*&"2"?)Q85[C*&QK65\FTO %ML'5X!;A0& 8'-D?D*<'GU MI!2Y[F;)*"<8&!':QKCX7@N-CR^RS.Z2WCTR"C\@ M8$I<]31D3O6V7AY$CP.F]%XO9*C0>;H:+S-,9/;ANU'F;&;7[=03N2H(HG=U M-\8TKJESMMJAZWBH+H_2YG.@F5%K7% MCK%8L#2)DCRAZU_%R2=/L*U5-I$K(&"#B@93$00*H"V=@X,0*:5C".XXD1 2 MT1'%2X RL1"_?7BPSO9=8E=0]!M6<,#*("#IM:?#(@+&42,"E2&HB/&+S3S+ MMH2_"1Y+B">$0/, 2(8^1)P@D[U0E8$^V5J0:"OFQ_WQ=+5,\M1V4* M@@Z+B@.+) @48%\Z#3<,55)4:GUDIVJ9M31'*W<%@-66ZOI681"=;G-D?/E; M?>UIR+_<18_"% %>2+#+7 _]-I/Z\-_4!(% AS'CI*22(J7U\4+"8N>1< ZQ$7 >N@B8.UM$:!V6Z8($>/2[2I-UAA(3MBI=@U%AV6=#XLT M*%1@?^"848>@0XSKC)9%BC.9GI]OBOU?B0^65@(Z9SDMNVS622UMHB 8Z7)F MI+4LD\XUQ$BJ77.QC9.!4AJEFRW M'YH!Q$'@-,0A\.B,#!H_R2BDPJHK85Y(^L;2+PV29& M$P5$BMT90$@M1J7:SPO:9?:(>I%5_NX0V$!([OAU[4[3VEO;5FU S'0:A-[A MKG)^'-;&992G5RQS(G\O(GDA7W".*V]@>R&YZYK((,.1TGIA8;'! M:?IYFR649/!$I*G_.@(:-GY[Q% & 5*O/?AW2.H(I$(<4W,K&.;-\[C"Q#PG&_!M MA_X05P0--:\XZM,'0=- DSI315C[Y+H(1#+29S:C9G)[>(G7$CE>&5L,:@OC MAB((1D!;T+*X^5L!?G+G;5=I$EVE#,-765H:QQGS3'M:LKR#(" "3%=0BKQ" MB JEE_[_C.D3WS[GT?Z.LX@0^9155H]6?=??!D:[9>9-36K3-"@T(,[>XA<@ M\% %:M3QH3%C^;R8)Q\:E]G<6/2T>,3B -YN\TS.H,(8?!6\,\CQ[84!#=!N M,G1$!(3> )O0#8P=+LLL_BQT] M=9QA#(AU??8VN#GZR5QO8! 0OM4M=*J7H68%:"6?$:NJ0+_+2E!1B^WWRYN; MKL4GL5EM$G^M<$;$EO\"4$L#!!0 ( ^3;E6VM< '6 < -]7 5 M96UM82TR,#(R,3$Q-%]P&ULS9Q=4]LX%(;O=V;_@S=['4)"VUTH; =2 MTLF4 DMHN[LW'<56$@VRE)%DDOS[E>PXS8M[M%Q*Z(BE@D3TXO6UU'[LO MD?TY_ZW=C@:,\N0L^BCC]E!,Y/OHEJ3T+/I$!57$2/4^^D9XYK;( >-417V9 MSCDUU'Y1-'P6O3WJOAM'[3:@WF]4)%)]?1ANZIT9,]=GG_Q3%SSD33V?NUYAH&EE>0I\M-;MHN7;7S2Y.CJ2: M=GK'Q]W./U]N1O&,IJ3-A.,6TU99RM525:Y[>GK:R;\MI0?*Y5CQLHV33MF= M3[342:N$GQ-4 MDM,'.HG<7QN]3:LT34FF4YJPF' 7M8Y3=/K2[I6VNWG9F:*3BY93VB9ZO6ZW M^\8U\/N.R*SF=N_4S.UV T[1>C2V'V*)F5%KOT7=<\P MXTJL=YMNU';[6);:!NW'0KGN3=D?+N.=+G 7"[GGM]RO<^*:QD=3^=Q)*.LX M!NY##B,'8?_YD3=T.=9&D=B4-7$RICRO_X?5[$DZ#?2J)/%H:ZSNU*YBOT_; MD;M4<2150I5E7=9%5+P3K\-==*WHS(FR%;7C&>.;4$^43'UTUB2DIZ/;H&P3 MS="\M.TGK@\#3J;5./>P\T"ES_75=<2=>ZC:&QP5/$2#X$\R1(N@6*0*70F2$/]"Y5#7@=Y5 WF\P M>5=Y0\+\=T:4H8JO(*0/Q$#8;S%A>QPB\7Y41&CF^$" 'ZJ!Q-^A7GAX/"(A M'\THYRZ9(P*TEU?I@=C_P,3N]_D*P%\_N_.[/;7 V6\5 >+_\[7@/W"+%(%[ MJIA,["E= =@?B('43S&I>QRB\KX6"93V1@K.?_!A[]E#0CU@.B:\Z-' ;M-A MW!5R*'*4G+/6)BKV?RE18.A;8BARE#2TQF+#P/N94CN="8XJ?C44.4H"6F>R M8>;7PC"SZ@1XKNOA#)&R35# MYE X]ZT?1?A0)'3YF:Y"H ^D4-(H.6;0'@KJ>\52HE8C%MNK<(E#U*6@FRBQ*"H8BEFLNMV\5]F=GC<=6727!( MKRD(#0=*OOD"ZRA!N4P2BTNO_]PP0;NA4%3*P<^(\ (0L/E*L/=>AKT'QXZ2 MA];:?"783UZ&_02.'247K;6)B;UO/]ZI1[GP/('VBJ'(47+1&HN8P/,SS9VZ M5_*9%;.CZJ@?E("B1TQ1PV91=_CB) _9VTLEE#=BNEIM#I/SO=2&\/_8O.Y* MLEH/98Z8N(:,-GV#L8B[NVGAFTJT)X'R1=Y(]^QC)D7P?NRA"LH5)9/TF6IZX'6SB;7WT-_Z&CR##658W;?1,,;O MBAG;@[Y,TTRL[]%XGHIYI%"\*.E?T%[#J$>2LY@9)J9?[!6B8H174.5!!6:.D?#Y3#;.]E8^*N%5[HU4Z MEMR_/*12""6,DN %K#4,>:%Z&<^(F%+_[(5J)10P M2J87,H3\&]D,U=H\4"AQGB63(7M.HLX09FA1=&C!!1&Q3JLVZ-D]V M7E\*&@"<-91 TRBW][]3SC\+N1 C2K04-"DN]4-W^+U%H%% ?(988Q MI83SJTPS075P;-D30B$CSGFMM(8"^3JE:FH'M4]*+LQLO;8S!-M3 H=<69K MT"H._.7/=>3%^K<@^0HU^.T$B-B])K%>NQ'';B)%<287"5$>ZB$]E#OJPDJ_ MT8;)WYD95=O73WEGAC9O"TUZJ"\%C0)*N@HUC7-NW5K)'SRU[NB@O!$3TRIC M.&NFLC%G\8!+$KPNWY%!^2)FH16V4/!>$?&DLKF)5_=*QI2ZQR=Z<[0!$B)@ M!="0(.:G+T*!<[M IJE;3"3CI]',FM9WFD7 !JM0 '0 @ '^$0 96$Q-C@U M,C!E>#DY+3%?96UM875S;&EF92YH=&U02P$"% ,4 " /DVY5Y81^!E0# M #(# $0 @ $B*@ 96UM82TR,#(R,3$Q-"YX&UL4$L! A0#% @ #Y-N5;:UP =8!P WU< M !4 ( !UC@ &5M;6$M,C R,C$Q,31?<')E+GAM;%!+!08 1 !0 % %@! !A0 ! end